← Leaderboards
Michael P Dube
Indiana Univ-Purdue Univ At Indianapolis
$3,435,340
Attributed
$3,435,340
Total exposure
29
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $828.1K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$3,435,340 · 29
By mechanism
R01$1,998,987 · 1
M01$1,436,353 · 28
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Md Michael Frank$0
- Michael J Econs$17,934,951
- Samir Kumar Gupta$7,772,068
- Mitchell Goldman$10,867,864
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationPatient Oriented ResearchAids TherapyAntiaids AgentUnited States National Institutes Of HealthFundingResearch PersonnelProtease InhibitorResourcesInstitutionSourceComputer Retrieval Of Information On Scientific Projects DatabaseHiv InfectionsGrantLipid MetabolismIndinavirVascular EndotheliumBloodGlucose Clamp TechniqueInsulin Sensitivity /ResistanceHyperinsulinismCombination Chemotherapy
Grant awards (41)
EFFECT OF HIV-1 PROTEASE INHIBITORS ON ENDOTHELIAL FUNCTION AND GLUCOSE$268,701
M01 · FY2007 · RR · contact PI
CROSS-SECTIONAL AND LONGITUDINAL STUDY OF ENDOTHELIAL FUNCTION BY BRACHIAL FLOW-$150,551
M01 · FY2007 · RR · contact PI
SWITCH TO ATAZANAVIR AND BRACHIAL ARTERY REACTIVITY (SABAR) STUDY: ENDOTHELIA$20,009
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EZETIMIBE (ZETIA?)$7,624
M01 · FY2007 · RR · contact PI
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$5,716
M01 · FY2007 · RR · contact PI
A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF URIDINE$4,765
M01 · FY2007 · RR · contact PI
PILOT STUDY TO ESTABLISH THE USE OF BRACHIAL ULTRASOUND TO MEASURE VASCULAR R$3,251
M01 · FY2007 · RR · contact PI
EFFECT OF HIV-1 PROTEASE INHIBITORS ON ENDOTHELIAL FUNCTION AND GLUCOSE$76,752
M01 · FY2006 · RR · contact PI
EFFECT OF A PROTEASE INHIBITOR-CONTAINING OR A NON-PROTEASE INHIBITOR-CONTAINING$63,595
M01 · FY2006 · RR · contact PI
A PHASE II TRIAL OF THE EFFECT OF COMBINATION THERAPY WITH FISH OIL SUPPLEMEN$20,467
M01 · FY2006 · RR · contact PI
PILOT STUDY TO ESTABLISH THE USE OF BRACHIAL ULTRASOUND TO MEASURE VASCULAR R$7,071
M01 · FY2006 · RR · contact PI
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$5,849
M01 · FY2006 · RR · contact PI
A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA$3,656
M01 · FY2006 · RR · contact PI
A PHASE IIIB, OPEN-LABEL, RANDOMIZED, MULTI-CENTER STUDY COMPARING THE ANTIVI$2,193
M01 · FY2006 · RR · contact PI
TRIAL OF PHYSIOLOGIC TESTOSTERONE SUPPLEMENTATION FOR HIV-POSITIVE(A5079)$2,193
M01 · FY2006 · RR · contact PI
IMMUNO & VIRO INDICES TO STUDY THE HIV DISEASE PROGRESSION ASSOC W/AGING$1,463
M01 · FY2006 · RR · contact PI
Endothelial Dysfunction Due to HIV-1 Protease Inhibitors$411,884
R01 · FY2005 · HL
EFFECT OF HIV-1 PROTEASE INHIBITORS ON ENDOTHELIAL FUNCTION AND GLUCOSE$176,355
M01 · FY2005 · RR
EFFECT OF A PROTEASE INHIBITOR-CONTAINING OR A NON-PROTEASE INHIBITOR-CONTAINING$131,074
M01 · FY2005 · RR
STUDY OF METFORMIN &ROSIGLITAZONE ALONE/IN COMBO IN HIV-INFECTED PTS$30,981
M01 · FY2005 · RR
EXTENDED-RELEASE NIACIN FOR THE TREATMENT OF ELEVATED NON-HDL CHOLESTEROL$22,242
M01 · FY2005 · RR
A PHASE II TRIAL OF THE EFFECT OF COMBINATION THERAPY WITH FISH OIL SUPPLEMEN$19,859
M01 · FY2005 · RR
IMMUNO &VIRO INDICES TO STUDY THE HIV DISEASE PROGRESSION ASSOC W/AGING$13,505
M01 · FY2005 · RR
TRIAL OF PHYSIOLOGIC TESTOSTERONE SUPPLEMENTATION FOR HIV-POSITIVE(A5079)$10,326
M01 · FY2005 · RR
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$4,766
M01 · FY2005 · RR
THYMIDINE ANALOGUE SUBSTITUTION OR CHANGE TO A NUCLEOSIDE-SPARING REGIMEN$3,973
M01 · FY2005 · RR
A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA$2,383
M01 · FY2005 · RR
ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE MINERAL DENSITY$799
M01 · FY2005 · RR
Endothelial Dysfunction Due to HIV-1 Protease Inhibitors$553,109
R01 · FY2004 · HL
EFFECT OF HIV-1 PROTEASE INHIBITORS ON ENDOTHELIAL FUNCTION AND GLUCOSE$237,089
M01 · FY2004 · RR
EXTENDED-RELEASE NIACIN FOR THE TREATMENT OF ELEVATED NON-HDL CHOLESTEROL$40,421
M01 · FY2004 · RR
THYMIDINE ANALOGUE SUBSTITUTION OR CHANGE TO A NUCLEOSIDE-SPARING REGIMEN$31,872
M01 · FY2004 · RR
STUDY OF METFORMIN &ROSIGLITAZONE ALONE/IN COMBO IN HIV-INFECTED PTS.$26,429
M01 · FY2004 · RR
Trial of Physiologic Testosterone Supplementation for HIV-Positive(A5079)$14,769
M01 · FY2004 · RR
Immuno &Viro indices to study the HIV disease progression assoc. w/Aging$10,884
M01 · FY2004 · RR
Plan for Obtaining Informed Consent to use Stored Human Biological Materials$8,552
M01 · FY2004 · RR
EFFECT OF A PROTEASE INHIBITOR-CONTAINING OR A NON-PROTEASE INHIBITOR-CONTAINING$3,109
M01 · FY2004 · RR
ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE MINERAL DENSITY$2,332
M01 · FY2004 · RR
Temporary Cessation of ART &Resistance testing in response to Salvage therapy$777
M01 · FY2004 · RR
Endothelial Dysfunction Due to HIV-1 Protease Inhibitors$581,124
R01 · FY2003 · HL
Endothelial Dysfunction Due to HIV-1 Protease Inhibitors$452,870
R01 · FY2002 · HL